Elam Marcus L, Johnson Sarah A, Hooshmand Shirin, Feresin Rafaela G, Payton Mark E, Gu Jennifer, Arjmandi Bahram H
1 Department of Nutrition, Food and Exercise Sciences, Florida State University , Tallahassee, Florida, USA .
J Med Food. 2015 Mar;18(3):324-31. doi: 10.1089/jmf.2014.0100. Epub 2014 Oct 14.
Menopause leads to an increased risk for osteoporosis in women. Although drug therapies exist, increasing numbers of people prefer alternative therapies such as dietary supplements, for example, calcium, vitamin D, and collagen hydrolysates for the prevention and treatment of osteoporosis. We have previously shown that a 3-month intervention using a calcium-collagen chelate (CC) dietary supplement was efficacious in improving bone mineral density (BMD) and blood biomarkers of bone turnover in osteopenic postmenopausal women. This study reports the long-term efficacy of CC in reducing bone loss in postmenopausal women with osteopenia. Thirty-nine women were randomly assigned to one of two groups: 5 g of CC containing 500 mg of elemental calcium and 200 IU vitamin D (1,25-dihydroxyvitamin D3) or control (500 mg of calcium and 200 IU vitamin D) daily for 12 months. Total body, lumbar, and hip BMD were evaluated at baseline, 6 and 12 months using dual-energy X-ray absorptiometry. Blood was collected at baseline, 6 and 12 months to assess levels of blood biomarkers of bone turnover. Intent-to-treat (ITT) analysis was performed using repeated measures analysis of variance pairwise comparisons and multivariate analysis to assess time and group interactions. The loss of whole body BMD in women taking CC was substantially lower than that of the control group at 12 months in those who completed the study and the ITT analysis, respectively (CC: -1.33% and -0.33% vs. control: -3.75% and -2.17%; P=.026, P=.035). The CC group had significantly reduced levels of sclerostin and tartrate-resistant acid phosphatase isoform 5b (TRAP5b) (P<.05), and higher bone-specific alkaline phosphatase/TRAP5b ratio (P<.05) than control at 6 months. These results support the use of CC in reducing bone loss in osteopenic postmenopausal women.
绝经会增加女性患骨质疏松症的风险。尽管存在药物疗法，但越来越多的人倾向于选择替代疗法，如膳食补充剂，例如钙、维生素D和水解胶原蛋白，用于预防和治疗骨质疏松症。我们之前已经表明，使用钙 - 胶原蛋白螯合物（CC）膳食补充剂进行为期3个月的干预，对改善骨质减少的绝经后女性的骨矿物质密度（BMD）和骨转换的血液生物标志物是有效的。本研究报告了CC在减少骨质减少的绝经后女性骨质流失方面的长期疗效。39名女性被随机分配到两组中的一组：每天服用5克含500毫克元素钙和200国际单位维生素D（1,25 - 二羟基维生素D3）的CC或对照组（500毫克钙和200国际单位维生素D），持续12个月。在基线、6个月和12个月时，使用双能X线吸收法评估全身、腰椎和髋部的骨密度。在基线、6个月和12个月时采集血液，以评估骨转换的血液生物标志物水平。使用重复测量方差分析、成对比较和多变量分析进行意向性治疗（ITT）分析，以评估时间和组间相互作用。在完成研究的人群和ITT分析中，服用CC的女性在12个月时全身骨密度的降低分别显著低于对照组（CC：-1.33%和-0.33%，对照组：-3.75%和-2.17%；P = 0.026，P = 0.035）。在6个月时，CC组的硬化蛋白和抗酒石酸酸性磷酸酶同工型5b（TRAP5b）水平显著降低（P < 0.05），且骨特异性碱性磷酸酶/TRAP5b比值高于对照组（P < 0.05）。这些结果支持使用CC来减少骨质减少的绝经后女性的骨质流失。
